1. Home
  2. NRXP vs WYY Comparison

NRXP vs WYY Comparison

Compare NRXP & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXP
  • WYY
  • Stock Information
  • Founded
  • NRXP 2015
  • WYY 1991
  • Country
  • NRXP United States
  • WYY United States
  • Employees
  • NRXP N/A
  • WYY N/A
  • Industry
  • NRXP Biotechnology: Pharmaceutical Preparations
  • WYY EDP Services
  • Sector
  • NRXP Health Care
  • WYY Technology
  • Exchange
  • NRXP Nasdaq
  • WYY Nasdaq
  • Market Cap
  • NRXP 32.6M
  • WYY 33.6M
  • IPO Year
  • NRXP N/A
  • WYY 1998
  • Fundamental
  • Price
  • NRXP $3.02
  • WYY $3.11
  • Analyst Decision
  • NRXP Strong Buy
  • WYY Strong Buy
  • Analyst Count
  • NRXP 4
  • WYY 1
  • Target Price
  • NRXP $28.50
  • WYY $7.00
  • AVG Volume (30 Days)
  • NRXP 187.5K
  • WYY 65.1K
  • Earning Date
  • NRXP 08-13-2025
  • WYY 08-13-2025
  • Dividend Yield
  • NRXP N/A
  • WYY N/A
  • EPS Growth
  • NRXP N/A
  • WYY N/A
  • EPS
  • NRXP N/A
  • WYY N/A
  • Revenue
  • NRXP N/A
  • WYY $142,582,209.00
  • Revenue This Year
  • NRXP N/A
  • WYY $10.84
  • Revenue Next Year
  • NRXP N/A
  • WYY $12.37
  • P/E Ratio
  • NRXP N/A
  • WYY N/A
  • Revenue Growth
  • NRXP N/A
  • WYY 24.03
  • 52 Week Low
  • NRXP $1.10
  • WYY $2.19
  • 52 Week High
  • NRXP $6.01
  • WYY $6.25
  • Technical
  • Relative Strength Index (RSI)
  • NRXP 43.71
  • WYY 40.96
  • Support Level
  • NRXP $2.89
  • WYY $3.05
  • Resistance Level
  • NRXP $3.53
  • WYY $3.38
  • Average True Range (ATR)
  • NRXP 0.15
  • WYY 0.16
  • MACD
  • NRXP -0.06
  • WYY 0.00
  • Stochastic Oscillator
  • NRXP 18.97
  • WYY 2.44

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

Share on Social Networks: